| Identification | Back Directory | [Name]
6H-Pyrimido[4,5-b][1,4]benzodiazepin-6-one, 5,11-dihydro-5,11-dimethyl-2-[[1-(4-piperidinyl)-1H-pyrazol-4-yl]amino]-, 2,2,2-trifluoroacetate (1:1) | [CAS]
2436579-93-8 | [Synonyms]
XMD-17-51 Trifluoroacetate (1628614-50-5 free base)
XMD 17 51 Trifluoroacetate,XMD1751 Trifluoroacetate
6H-Pyrimido[4,5-b][1,4]benzodiazepin-6-one, 5,11-dihydro-5,11-dimethyl-2-[[1-(4-piperidinyl)-1H-pyrazol-4-yl]amino]-, 2,2,2-trifluoroacetate (1:1) | [Molecular Formula]
C23H25F3N8O3 | [MOL File]
2436579-93-8.mol | [Molecular Weight]
518.5 |
| Hazard Information | Back Directory | [Uses]
XMD-17-51 TFA is a pyrimido-diazepinone compound that is able to modulate protein kinases[1]. | [References]
[1] WO 2014145909 A2.
[2] Yang WQ, Zhao WJ, Zhu LL, et al. XMD-17-51 Inhibits DCLK1 Kinase and Prevents Lung Cancer Progression. Front Pharmacol. 2021;12:603453. DOI:10.3389/fphar.2021.603453 |
|
|